Abstracts tagged "Rheumatoid Factor"

Abstract Number: 1648 • ACR Convergence 2021
Increasing Rates of Positivity of Autoantibodies Indicates a Shorter Time-to-Diagnosis of Future Rheumatoid Arthritis
Dylan Bergstedt¹, Ryan Peterson², Marie Feser¹, LauraKay Moss¹, Geoffrey Thiele³, Ted Mikuls³, Jess Edison⁴, V. Michael Holers¹ and Kevin Deane⁵, ¹University of Colorado Denver, Aurora, CO, ²Colorado School of Public Health, Aurora, CO, ³University of Nebraska Medical Center, Omaha, NE, ⁴Walter Reed National Military Medical Center, Bethesda, MD, ⁵University of Colorado Denver, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations in autoantibodies to citrullinated protein antigens (ACPA) and rheumatoid factor (RF)…
Abstract Number: 1654 • ACR Convergence 2021
Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL
Azamat Satybaldyev, Galina Gridneva, Anna Misiyuk, Natalia Demidova, Kamalia Kasumova and Evgeny Nasonov, V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia
Background/Purpose: Comparison of frequency of different clinical features of the natural course at the stage of early rheumatoid arthritis (RA) in patients with young and…
Abstract Number: 0157 • ACR Convergence 2020
Early Arthritis Global Assesment: What Differences Exist Between Patients and Physicians?
Cristina Valero¹, Noelia Garcia¹, Juan Pablo Baldivieso², Ana Ortiz³, Sebastian Rodriguez² and Isidoro González-Álvaro³, ¹Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ²Hospital de La Princesa, Madrid, Madrid, Spain, ³Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: In recent years there is increasing evidence of the relevance of including the assessment of the different aspects of rheumatoid arthritis (RA) from the…
Abstract Number: 0182 • ACR Convergence 2020
Chronic Kidney Disease Is Underestimated in Patients with Rheumatoid Arthritis – Real World Data Gathered from a Network of Rheumatologists
Stefan Kleinert¹, Peter Bartz-Bazzanella², Cay von der Decken³, Kirsten Karberg⁴, Florian Schuch⁵, Georg Gauler⁶, Patrick Wurth⁷, Susanna Spaethling-Mestekemper⁸, Christoph Kuhn⁹, Matthias Englbrecht¹⁰, Wolfgang Vorbrueggen¹¹ and Martin Welcker¹², ¹Rheumatology-Nephrology Practice, Erlangen, Germany, ²Department of Rheumatology, Internal Medicine, Rhein-Maas-Hospital, Wuerselen, Germany, ³Medical Centre Stolberg, Stolberg, Germany, ⁴Practice for Rheumatology and Internal Medicine, Berlin, Germany, ⁵Rheumatology-Nephrology Practice, Erlangen, ⁶Rheumatology Practice, Osnabrueck, ⁷Rheumatology Practice, Osnabrueck, Germany, ⁸Rheumatology Group Practice, Muenchen, Germany, ⁹Rheumatology Practice, Karlsruhe, ¹⁰Freelance Healthcare Data Scientist, Eckental, Germany, ¹¹Foundation for fostering rheumatology, Wuerselen, Germany, ¹²MVZ für Rheumatologie Dr. M. Welcker, Planegg, Germany
Background/Purpose: Patient registries have become a common approach to learn from patient-related data by prospectively including large numbers of individuals into a sample followed over…
Abstract Number: 0754 • ACR Convergence 2020
The Association Between Continuous Decreases in Serum RF Titers and Radiographic Remission of Joint Damage in RA Patients Treated with Biological or Targeted Synthetic DMARDs
Takayoshi Owada¹, Ayae Tanaka², Hirokuni Hirata¹, Masafumi Arima³, Yasutsugu Fukushima¹ and Kazuhiro Kurasawa³, ¹Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan, ²Dokkyo Medical University, Shimotsuga-Gun, Japan, ³Dokkyo Medical University, Mibu, Shimotsugagun, Tochigi, Japan
Background/Purpose: Rheumatoid factors (RFs) are RA-related autoantibodies like anti-cyclic citrullinated peptide antibodies, and are used for classifying and diagnosing RA. In addition, positivity and high…
Abstract Number: 0758 • ACR Convergence 2020
Anti-citrullinated Protein Antibodies Are Associated with Functional Disability in Unaffected First-degree Relatives of Rheumatoid Arthritis Patients
Dana Wiens¹, Irene Smolik¹, Xiaobo Meng¹, Vidyanand Anaparti¹, Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: The preclinical stage of Rheumatoid Arthritis (RA) is characterized by seropositivity for anti-citrullinated protein antibodies (ACPA). We (PubMed ID 30861615), and others, have shown that ACPA seropositivity…
Abstract Number: 0768 • ACR Convergence 2020
Dynamics of Follicular Helper T Cells Subsets in Rheumatoid Arthritis Patients Before and After Treatment
Paola Virginia Ferrero¹, Luisina Onofrio¹, Cristina del Valle Acosta¹, Estefania Raquel Zacca¹, Nicolas Eric Ponce², Eduardo Mussano¹, Ignacio Isaac Cadile¹, Laura Onetti¹, Marina Werner¹, Alicia Beatriz Costantino¹, Eva Virginia Acosta Rodriguez³ and Adriana Gruppi², ¹HOSPITAL NACIONAL DE CLINICAS, FACULTAD DE MEDICINA, UNIVERSIDAD NACIONAL DE CORDOBA, CORDOBA, Cordoba, Argentina, ²FACULTAD DE CIENCIAS QUIMICAS, UNIVERSIDAD NACIONAL DE CORDOBA. CENTRO DE INVESTIGACIONES EN BIOQUIMICA CLINICA E INMUNOLOGIA, CORDOBA, Cordoba, Argentina, ³FACULTAD DE CIENCIAS QUIMICAS, UNIVERSIDAD NACIONAL DE CORDOBA. CENTRO DE INVESTIGACIONES EN BIOQUIMICA CLINICA E INMUNOLOGIA, CORDOBA, Argentina
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by the production of autoantibodies like rheumatoid factor and anti- citrullinated protein. CD4+ follicular helper T…
Abstract Number: 0813 • ACR Convergence 2020
Treatment Outcomes in Patients with Seropositive versus Seronegative Rheumatoid Arthritis in Czech Registry ATTRA Treated with JAK Inhibitors
Karel Pavelka¹ and Zlatuše Křístková², ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
Background/Purpose: Seropositivity / seronegativity in RA may have influence on response to bDMARDs or tsDMARDs. There is incomplete knowledge of differences in efficacy of JAK…
Abstract Number: 1698 • ACR Convergence 2020
Polyarthritis Workup in Primary Care Setting : How Are We Doing?
Ruhani Desai¹, Cassandra Calabrese², Neel Patel³ and Jessica Donato⁴, ¹Cleveland Clinic Foundation, DeLand, FL, ²Cleveland Clinic, Cleveland, OH, ³Case Western Reserve University, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland
Background/Purpose: Joint pain is a common presenting complaint in Primary Care with around 54.4 million adults diagnosed with some form of arthritis per 2013 CDC survey. Polyarthritis…
Abstract Number: 1720 • ACR Convergence 2020
Factors Associated with an Increased Risk of Imminent Rheumatoid Arthritis in ACPA+ Individuals
Hyoun-Ah Kim¹, Ryan Peterson², Gary Firestein³, David Boyle⁴, Jane Buckner⁵, Sylvia Posso⁶, Eddie James⁵, William Robinson⁷, Jaron Arbet², LauraKay Moss⁸, Roger Gilmore⁸, Lindsay Hartje⁸, Saman Barzideh⁸, Jennifer Seifert⁹, Navin Rao¹⁰, Frédéric Baribaud¹¹, Sunil Nagpal¹², Alyssa Johnson¹³, V Michael Holers¹⁴ and Kevin D. Deane¹⁵, ¹University of Colorado Anschutz Medical Campus and Ajou University School of Medicine, Aurora, CO, ²Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, ³University of California, San Diego, La Jolla, CA, ⁴UC San Diego, San Diego, CA, ⁵Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Stanford University, Palo Alto, CA, ⁸University of Colorado Anschutz Medical Campus, Aurora, CO, ⁹Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Littleton, CO, ¹⁰Janssen R&D, Spring House, PA, ¹¹Janssen Research & Development, LLC, Spring House, PA, ¹²Janssen Reserach and Development, Spring House, PA, ¹³Janssen Research and Development, Spring House, PA, ¹⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ¹⁵2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado
Background/Purpose: Individuals at high-risk for future rheumatoid arthritis (RA) may be identified by screening for circulating RA-related autoantibodies including antibodies to citrullinated protein antigens (ACPA).…
Abstract Number: 1721 • ACR Convergence 2020
Increasing Autoantibody Positivity During Pre-RA Is Associated with the Imminent Development of Classifiable RA
Heinrich-Karl Greenblatt¹, Ted Mikuls², Jess Edison³, Marie Feser⁴, Mark Parish⁵, LauraKay Moss⁵, Elizabeth Mewshaw⁶ and Kevin D. Deane⁷, ¹University of Colorado School of Medicine, Aurora, CO, ²University of Nebraska Medical Center, Omaha, NE, ³Walter Reed National Military Medical Center, Bethesda, ⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Walter Reed National Military Medical Center, Bethesda, MD, ⁷2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado
Background/Purpose: Autoantibodies including rheumatoid factor (RF) and antibodies to citrullinated protein antigens (ACPA) may be elevated during a period that can be termed ‘Pre-RA’. In…
Abstract Number: 1753 • ACR Convergence 2020
Substantial Work Limitations in Patients with Rheumatoid Arthritis Despite Optimal Treat-to-Target (T2T) Drug Therapy Intervention
Sara Eileen Meyer¹, Julianna Rachel Hoeper², Kirsten Hoeper¹, Torsten Witte³ and Dirk Meyer-Olson⁴, ¹Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., Hanover, Germany, ²Center for Health Economics Research Hannover, Leibniz Universität Hannover, Hannover, Hanover, Germany, ³Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., Hannover, Germany, ⁴Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., m&i Fachklinik Bad Pyrmont und Medizinisches Forschungszentrum Weserbergland, Hanover, Germany
Background/Purpose: Rheumatoid arthritis (RA) is associated with restrictions on occupational participation caused by periods of sick leave (absenteeism), reduced productivity at work due to disease…
Abstract Number: 145 • 2020 Pediatric Rheumatology Symposium
Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA
Saumya Joshi¹, Yujuan Zhang ¹ and Trevor Davis ², ¹Tufts Medical Center, Boston, Massachusetts, ²Norwell, Massachusetts
Background/Purpose: Despite being a well-established biomarker for classification of aggressive bony disease in adults with RA, ACPA have not yet been described in the ILAR…
Abstract Number: 51 • 2019 ACR/ARP Annual Meeting
Cigarette Smoking Has Different Impacts on ACPA and RF Production Depending on Shared Epitope Allele Status in Japanese RA Patients; A Study with the Two Independent Japanese Cohorts (IORRA and KURAMA)
Yuki Ishikawa¹, Motomu Hashimoto ², Katsunori Ikari ³, Koichiro Ohmura ⁴, Masao Tanaka ⁴, Hiromu Ito ⁴, Atsuo Taniguchi ³, Hisashi Yamanaka ³, Tsuneyo Mimori ⁴ and Chikashi Terao ⁵, ¹Joslin Diabes Center, Boston, MA, ²Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Tokyo Women’s Medical University, Tokyo, Japan, ⁴Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵RIKEN, Tokyo, Japan
Background/Purpose: In rheumatoid arthritis (RA), cigarette smoking affects both rheumatoid factor (RF) and anti-citrullinated cyclic peptide/protein antibody (ACPA) production, but its association in relation to…
Abstract Number: 464 • 2019 ACR/ARP Annual Meeting
Continuous Decrease in Serum RF Titer During Anti-TNF Therapy Was Associated with Suppression in Progression of RA Joint Damage
Takayoshi Owada¹, Kazuhiro Kurasawa ¹, Yuta Takamura ¹, Toshiyuki Miyao ¹, Ayae Tanaka ¹, Ryutaro Yamazaki ¹, Satoko Arai ¹, Reika Maezawa ¹ and Masafumi Arima ¹, ¹Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi, Japan
Background/Purpose: A number of studies have investigated the association between serum RF and joint damage in early and established RA patients, and positive and high-titer…

« Previous Page
1
…
3
4
5
6
7
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].